Pembrolizumab use for the treatment of advanced melanoma

References

• Worldwide data. World cancer research fund international. [cited 2017 Feb 17]. Available from: http://www.wcrf.org/int/cancer-facts-figures/worldwide-data.
   Google Scholar
• Skin Cancers. World health organization. [cited 2017 Feb 17]. Available from: http://www.who.int/uv/faq/skincancer/en/index1.html
   Google Scholar
• Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol. 2011;65:S17–S25.
   PubMed Web of Science ®Google Scholar
• Weir HK, Marrett LD, Cokkinides V, et al. Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006. J Am Acad Dermatol. 2011;65:S38–S49.
   PubMed Web of Science ®Google Scholar
• Merrill SJ, Subramanian M, Godar DE. Worldwide cutaneous malignant melanoma incidences analyzed by sex, age, and skin type over time (1955-2007): is HPV infection of androgenic hair follicular melanocytes a risk factor for developing melanoma exclusively in people of European- ancestry? Dermatoendocrinol. 2016;8(1):e1215391.
   PubMed Web of Science ®Google Scholar
• Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998–1012.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2014;383:816–827.
   PubMed Web of Science ®Google Scholar
• Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355:51–65.
   PubMed Web of Science ®Google Scholar
• Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v126–v132.
   PubMed Web of Science ®Google Scholar
• Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009;9:587–595.
   PubMed Web of Science ®Google Scholar
• Specenier P. Ipilimumab in melanoma. Expert Rev Anticancer Ther. 2012;12:1511–1521.
   PubMed Web of Science ®Google Scholar
• Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33:1191–1196.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–1894.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J. 1992;11:3887–3895.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21:4286–4293.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2:662–673.
   PubMed Web of Science ®Google Scholar
• Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002;32:634–643.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034.
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261–268.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–144.
   PubMed Web of Science ®Google Scholar
• Ribas A, Shin DS, Zaretsky J, et al. PD-1 blockade expands intratumoral memory T cells. Cancer Immunol Res. 2016;4:194–203.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–571.
   PubMed Web of Science ®Google Scholar
• Keytruda: EPAR public assessment report. European Medicines Agency. [cited 2017 Feb 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Public_assessment_report/human/003820/WC500190992.pdf
   Google Scholar
• Shimizu T, Seto T, Hirai F, et al. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest New Drugs. 2016;34:347–354.
   PubMed Web of Science ®Google Scholar
• Ahamadi M, Freshwater T, Prohn M, et al. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):49–57.
   PubMedGoogle Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–1117.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. Jama. 2016;315:1600–1609.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Hamid O, et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol. 2016;34(suppl):9503 (abstr).
   Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–918.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Dummer R, Hauschild A, et al. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016;67:46–54.
   PubMed Web of Science ®Google Scholar
• Hamid O, Puzanov I, Dummer R, et al. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab(ipi)-refractory melanoma. Ann Oncol. 2016;27:vi379 1107O (abstr).
   Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
   PubMed Web of Science ®Google Scholar
• Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006. J Clin Oncol. 2016;34(suppl):9504 (abstr).
   Google Scholar
• Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270–1271.
   PubMed Web of Science ®Google Scholar
• Kirchberger MC, Hauschild A, Schuler G, et al. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. Eur J Cancer. 2016;65:182–184.
   PubMed Web of Science ®Google Scholar
• Long GV, Atkinson V, Cebon J, et al. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort. J Clin Oncol. 2016;34(suppl):9506 (abstr).
   Google Scholar
• Davar D, Wang H, Chauvin JM, et al. Phase IB Study of pembrolizumab (Pembro) and pegylated- interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL). J Clin Oncol. 2016;34(suppl):9539 (abstr).
   Google Scholar
• Gangadhar TC, Hamid O, Smith DC, et al. Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: updated phase1 results from ECHO-202/KEYNOTE-037. Ann Oncol. 2016;27:vi381 1110PD (abstr).
   Google Scholar
• Karydis I, Chan PY, Wheater M, et al. Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology. 2016;5:e1143997.
   PubMed Web of Science ®Google Scholar
• Kottschade LA, McWilliams RR, Markovic SN, et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016;26:300–303.
   PubMed Web of Science ®Google Scholar
• Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122:3344–3353.
   PubMed Web of Science ®Google Scholar
• Munhoz RR, Shoushtari AN, Kuk D, et al. Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma. J Clin Oncol. 2016;34(suppl):9516 (abstr).
   Google Scholar
• Cho J, Ahn S, Yoo KH, et al. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Invest New Drugs. 2016;34(6):677–684.
   PubMed Web of Science ®Google Scholar
• Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016;122:3354–3362.
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non- small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open- label, phase 2 trial. Lancet Oncol. 2016;17:976–983.
   PubMed Web of Science ®Google Scholar
• Park JJ, Parakh S, Mendis S, et al. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Ann Oncol. 2016;27:vi383 1114PD (abstr).
   Google Scholar
• Cohen JV, Alomari AK, Vortmeyer AO, et al. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res. 2016;4:179–182.
   PubMed Web of Science ®Google Scholar
• Luttmann N, Gratz V, Haase O, et al. Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition. Melanoma Res. 2016;26:528–531.
   PubMed Web of Science ®Google Scholar
• Mohiuddin M, Park H, Hallmeyer S, et al. High-dose radiation as a dramatic, immunological primer in locally advanced melanoma. Cureus. 2015;7:e417.
   PubMedGoogle Scholar
• Olson AC, Patel K, Mowery YM, et al. Anti-PD-1 therapy and stereotactic radiation for melanoma and non-small cell lung cancer patients with brain metastases: a 2-institution series. Int J Radiat Oncol Biol Phys. 2016;96:E97 2238 (Abstr).
   Google Scholar
• Anderson ES, Postow MA, Young R, et al. Initial report on safety and lesion response of melanoma brain metastases after stereotactic radiosurgery or hypofractionated radiation therapy in patients receiving concurrent. Int J Radiat Oncol Biol Phys. 2016;96:E132 2321 (Abstr).
   Google Scholar
• Mowery YM, Patel K, Olson AC, et al. toxicity and survival for metastatic melanoma patients treated with anti-PD1 therapy and radiation treatment. Int J Radiat Oncol Biol Phys. 2016;96:S158 357 (Abstr).
   Google Scholar
• Ahmed KA, Abuodeh YA, Hogue C, et al. Outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF inhibitor, or conventional chemotherapy. Int J Radiat Oncol Biol Phys. 2016;96:S58 130 (Abstr).
   Google Scholar
• Liniker E, Menzies AM, Kong BY, et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 2016;5:e1214788.
   PubMed Web of Science ®Google Scholar
• Ribeiro GJ, Schmerling RA, Haddad CK, et al. Analysis of the abscopal effect with anti-PD1 therapy in patients with metastatic solid tumors. J Immunother. 2016;39:367–372.
   PubMed Web of Science ®Google Scholar
• Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–225.
   PubMed Web of Science ®Google Scholar
• Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190–209.
   PubMed Web of Science ®Google Scholar
• Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12–25.
   PubMed Web of Science ®Google Scholar
• Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;76–83.
   PubMedGoogle Scholar
• Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–1353.
   PubMed Web of Science ®Google Scholar
• Kahler KC, Hassel JC, Heinzerling L, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges. 2016;14:662–681.
   Web of Science ®Google Scholar
• Weber JS, Postow M, Lao CD, et al. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21:1230–1240..
   PubMed Web of Science ®Google Scholar
• de Filette J, Jansen Y, Schreuer M, et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab. 2016;101:4431–4439.
   PubMed Web of Science ®Google Scholar
• Aaberg MT, Aaberg TM Jr. Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep. 2016. Epub ahead of print. doi.org/10.1097/ICB.0000000000000368
   PubMedGoogle Scholar
• Diem S, Keller F, Ruesch R, et al. Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy? J Immunother. 2016;39:379–382.
   PubMed Web of Science ®Google Scholar
• Hanna KS, Rare A. Case of pembrolizumab-induced uveitis in a patient with metastatic melanoma. Pharmacotherapy. 2016;36(11):e183–e188.
   PubMed Web of Science ®Google Scholar
• Abu SK, Valdes-Navarro M, Lee S, et al. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2016;26:e46–e48.
   PubMed Web of Science ®Google Scholar
• Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol. 2016;51:e4–e6.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis. 2016;10:183–193.
   PubMed Web of Science ®Google Scholar
• Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta- analysis. JAMA Oncol. 2016;2(12):1607–1616.
   PubMed Web of Science ®Google Scholar
• Sehgal S, Velcheti V, Mukhopadhyay S, et al. Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity? Respir Med Case Rep. 2016;19:118–120.
   PubMed Web of Science ®Google Scholar
• Nguyen BH, Kuo J, Budiman A, et al. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res. 2017 Apr;27(2):152–154.
   PubMed Web of Science ®Google Scholar
• de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med. 2016;375:296–297.
   PubMed Web of Science ®Google Scholar
• Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016. pii: bcr2016215012. doi: 10.1136/bcr-2016-215012.
   Google Scholar
• Khoja L, Maurice C, Chappell M, et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res. 2016;4:175–178.
   PubMed Web of Science ®Google Scholar
• LaPorte J, Solh M, Ouanounou S. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma. J Oncol Pharm Pract. 2017;23(1):71–74.
   PubMed Web of Science ®Google Scholar
• Mandel JJ, Olar A, Aldape KD, et al. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014;344:229–231.
   PubMed Web of Science ®Google Scholar
• Aya F, Ruiz-Esquide V, Viladot M, et al. Vasculitic neuropathy induced by pembrolizumab. Ann Oncol. 2016. pii: mdw613. Epub ahead of print. doi: 10.1093/annonc/mdw613
   PubMed Web of Science ®Google Scholar
• Chae YK, Chiec L, Mohindra N, et al. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother. 2017;66(1):25–32.
   PubMed Web of Science ®Google Scholar
• Hansen E, Sahasrabudhe D, Sievert L. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother. 2016;65:765–767.
   PubMed Web of Science ®Google Scholar
• Martin-Liberal J, Furness AJ, Joshi K, et al. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother. 2015;64:765–767.
   PubMed Web of Science ®Google Scholar
• Gaudy C, Clevy C, Monestier S, et al. Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care. 2015;38:e182–e183.
   PubMed Web of Science ®Google Scholar
• Aleksova J, Lau PK, Soldatos G, et al. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. BMJ Case Rep. 2016;2016.pii: bcr2016217454. doi:10.1136/bcr-2016-217454
   PubMedGoogle Scholar
• Alabed YZ, Aghayev A, Sakellis C, et al. Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT. Clin Nucl Med. 2015;40:e528–e529.
   PubMed Web of Science ®Google Scholar
• Shenoy N, Esplin B, Barbosa N, et al. Pembrolizumab induced severe sclerodermoid reaction. Ann Oncol. 2016. Epub ahead of print. pii: mdw543.PMID:27742656. doi.org/10.1093/annonc/mdw543
   PubMed Web of Science ®Google Scholar
• Garel B, Kramkimel N, Trouvin AP, et al. Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma. Joint Bone Spine. 2017;84(2):233–234.
   PubMed Web of Science ®Google Scholar
• Salmon JH, Lambrecht I, Brochot P, et al. A case of arthritis under pembrolizumab. Joint Bone Spine. 2016; 84(2):243–244.
   Web of Science ®Google Scholar
• Chan MM, Kefford RF, Carlino M, et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother. 2015;38:37–39.
   PubMed Web of Science ®Google Scholar
• Vallet H, Gaillet A, Weiss N, et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol. 2016;27:1352–1353.
   PubMed Web of Science ®Google Scholar
• Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res. 2014;2:15–18.
   PubMed Web of Science ®Google Scholar
• Bonigen J, Raynaud-Donzel C, Hureaux J, et al. Anti-PD1-induced psoriasis. A study of 21 patients. J Eur Acad Dermatol Venereol. 2016. Epub ahead of print. doi: 10.1111/jdv.14011.
   PubMedGoogle Scholar
• Totonchy MB, Ezaldein HH, Ko CJ, et al. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatol. 2016;152:590–592.
   PubMed Web of Science ®Google Scholar
• Sahuquillo-Torralba A, Ballester-Sanchez R, Pujol-Marco C, et al. Pembrolizumab: a new drug that can induce exacerbations of psoriasis. Actas Dermosifiliogr. 2016;107:264–266.
   PubMed Web of Science ®Google Scholar
• Firwana B, Ravilla R, Raval M, et al. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2016. Epub ahead of print. pii: 1078155216667635.PMID:27590328 doi.org/10.1177/1078155216667635
   PubMedGoogle Scholar
• Cousin S, Toulmonde M, Kind M, et al. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol. 2016;27:1178–1179.
   PubMed Web of Science ®Google Scholar
• Cousin S, Italiano A. Pulmonary sarcoidosis or post-immunotherapy granulomatous reaction induced by the anti-PD-1 monoclonal antibody pembrolizumab: the terminology is not the key point. Ann Oncol. 2016;27:1974–1975.
   PubMed Web of Science ®Google Scholar
• Cotliar J, Querfeld C, Boswell WJ, et al. Pembrolizumab-associated sarcoidosis. JAAD Case Rep. 2016;2:290–293.
   PubMedGoogle Scholar
• Paydas S. Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology? Ann Oncol. 2016;27:1650–1651.
   PubMed Web of Science ®Google Scholar
• Mutgi KA, Milhem M, Swick BL, et al. Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanoma. JAAD Case Rep. 2016;2:343–345.
   PubMedGoogle Scholar
• Joseph RW, Cappel M, Goedjen B, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3:18–22.
   PubMed Web of Science ®Google Scholar
• Parakh S, Nguyen R, Opie JM, et al. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. Australas J Dermatol. 2016. Epub ahead of print. doi: 10.1111/ajd.12488
   PubMedGoogle Scholar
• Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43:688–696.
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol. 2016;74:455–461.
   PubMed Web of Science ®Google Scholar
• Carlos G, Anforth R, Chou S, et al. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015;25:265–268.
   PubMed Web of Science ®Google Scholar
• Lomax AJ, Ge L, Anand S, et al. Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab. Australas J Dermatol. 2016;57:333–335. Epub ahead of print.
   Web of Science ®Google Scholar
• Baroudjian B, Lourenco N, Pages C, et al. Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res. 2016;26:308–311.
   PubMed Web of Science ®Google Scholar
• Zibelman M, Pollak N, Olszanski AJ. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer. 2016;4:8.
   PubMed Web of Science ®Google Scholar
• Le RA, Kempf E, Ackermann F, et al. Two cases of immune thrombocytopenia associated with pembrolizumab. Eur J Cancer. 2016;54:172–174.
   PubMed Web of Science ®Google Scholar
• Nair R, Gheith S, Nair SG. Immunotherapy-associated hemolytic anemia with pure red-cell aplasia. N Engl J Med. 2016;374:1096–1097.
   PubMed Web of Science ®Google Scholar
• Belliere J, Meyer N, Mazieres J, et al. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer. 2016;115(12):1457–1461.
   PubMed Web of Science ®Google Scholar
• Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis. 2016;68:287–291.
   PubMed Web of Science ®Google Scholar
• Bickel A, Koneth I, Enzler-Tschudy A, et al. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC Cancer. 2016;16:656.
   PubMed Web of Science ®Google Scholar
• Laubli H, Balmelli C, Bossard M, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11.
   PubMed Web of Science ®Google Scholar
• Uemura M, Trinh VA, Haymaker C, et al. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report. J Hematol Oncol. 2016;9:81.
   PubMed Web of Science ®Google Scholar
• Heidelberger V, Kramkimel N, Huillard O, et al. Sarcopenia associated with a body mass index (BMI) > 25 kg/m2 predicts severe acute toxicity of nivolumab and pembrolizumab in melanoma patients. Ann Oncol. 2016;27:vi389 1130P (abstr).
   Web of Science ®Google Scholar
• Chang R, Shirai K. Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ Case Rep. 2016. pii: bcr2016216426. doi: 10.1136/bcr-2016-216426
   Google Scholar
• Herz S, Hofer T, Papapanagiotou M, et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer. 2016;67:66–72.
   PubMed Web of Science ®Google Scholar
• Davar D, Wilson M, Pruckner C, et al. PD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Rep Oncol Med. 2015;2015:737389.
   PubMed Web of Science ®Google Scholar
• Singh AK, Porrata LF, Aljitawi O, et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma. Bone Marrow Transplant. 2016;51:1268–1270.
   PubMed Web of Science ®Google Scholar
• Kwong YL. Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation. Ann Hematol. 2016;95:1191–1192.
   PubMed Web of Science ®Google Scholar
• Maggiore U, Pascual J. The bad and the good news on cancer immunotherapy: implications for organ transplant recipients. Adv Chronic Kidney Dis. 2016;23:312–316.
   PubMed Web of Science ®Google Scholar
• Ma Q, Shilkrut M, Li M, et al. Prevalence of autoimmune comorbidities in patients with metastatic melanoma in the US. J Clin Oncol. 2016;34(suppl):9529 (abstr).
   Google Scholar
• Beck KM, Dong J, Geskin LJ, et al. Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid. J Immunother Cancer. 2016;4:20.
   PubMed Web of Science ®Google Scholar
• Maul LV, Weichenthal M, Kahler KC, et al. Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease. J Immunother. 2016;39:188–190.
   PubMed Web of Science ®Google Scholar
• Aya F, Fernandez-Martinez A, Gaba L, et al. Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab. Immunotherapy. 2016;8:687–692.
   PubMed Web of Science ®Google Scholar
• Bender C, Dimitrakopoulou-Strauss A, Enk A, et al. Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment. Ann Oncol. 2016;27:1353–1354.
   PubMed Web of Science ®Google Scholar
• Donia M, Pedersen M, Svane IM. Cancer immunotherapy in patients with preexisting autoimmune disorders. Semin Immunopathol. 2016. Epub ahead of print. doi.org/10.1007/s00281-016-0595-8.
   PubMedGoogle Scholar
• Lau KH, Kumar A, Yang IH, et al. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016;54:157–161.
   PubMed Web of Science ®Google Scholar
• Phadke SD, Ghabour R, Swick BL, et al. Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases. J Investig Med High Impact Case Rep. 2016;4:2324709616674316.
   Google Scholar
• Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve. 2016;54:506–507.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD1 therapy in patients with advanced melanoma and preexisting autoimune disorders or major toxicity with ipilimumab. J Clin Oncol. 2016;34(suppl):9515 (abstr).
   Google Scholar
• Gard G, Van Hagen T, Ariyapperuma M, et al. Safety of immune check-point inhibitors in patients with autoimmune conditions and advanced cancer. Ann Oncol. 2016;27:vi372 1084P (abstr).
   Web of Science ®Google Scholar
• Rai R, McQuade JL, Wang DY, et al. Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma. Ann Oncol. 2016;27:vi382–31113PD (abstr).
   Google Scholar
• Nishijima TF, Muss HB, Shachar SS, et al. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. Cancer Treat Rev. 2016;45:30–37.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510–1517.
   PubMed Web of Science ®Google Scholar
• Ades F, Yamaguchi N. WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results? Ecancermedicalscience. 2015;9:604.
   PubMed Web of Science ®Google Scholar
• Khoja L, Kibiro M, Metser U, et al. Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. Br J Cancer. 2016;115(10):1186–1192.
   PubMed Web of Science ®Google Scholar
• Kong BY, Menzies AM, Saunders CA, et al. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res. 2016;29:572–577.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Coinu A, Cabiddu M, et al. Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials. Medicine (Baltimore). 2016;95:e3997.
   PubMed Web of Science ®Google Scholar
• Jansen Y, Rozeman EA, Hojberg L, et al. Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO). Ann Oncol. 2016;27:vi388 1127P (abstr).
   Web of Science ®Google Scholar
• Diem S, Kasenda B, Spain L, et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer. 2016;114:256–261.
   PubMed Web of Science ®Google Scholar
• Nosrati A, Goldinger SM, Tsai KK, et al. Derivation and validation of a prediction scale for response to PD-1 monotherapy. J Clin Oncol. 2016;34(suppl):9514 (abstr).
   Google Scholar
• Goldinger SM, Tsai KK, Tumeh P, et al. Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma. J Clin Oncol. 2016;34(suppl):9549 (abstr).
   Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35–44.
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–829.
   PubMed Web of Science ®Google Scholar
• Shreders A, Joseph R, Peng C, et al. Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab. Cancer Immunol Res. 2016;4:569–573.
   PubMed Web of Science ®Google Scholar
• Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22(22):5487–5496.
   PubMed Web of Science ®Google Scholar
• Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152:45–51.
   PubMed Web of Science ®Google Scholar
• Kramkimel N, Heidelberger V, Huillard O, et al. Slow natural history predicts higher response rate to nivolumab and pembrolizumab in advanced melanoma patients. Ann Oncol. 2016;27:vi388 1126P (abstr).
   Web of Science ®Google Scholar
• Shukuya T, Mori K, Amann JM, et al. Relationship between overall survival and response or progression-free survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 antibodies. J Thorac Oncol. 2016;11:1927–1939.
   PubMed Web of Science ®Google Scholar
• Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10:e0130142.
   PubMed Web of Science ®Google Scholar
• Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34:4102–4109.
   PubMed Web of Science ®Google Scholar
• Daud A, Blank C, Robert C, et al. KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: efficacy by PD-L1 expression and line of therapy. J Clin Oncol. 2016;34(suppl):9513 (abstr).
   Google Scholar
• Abdel-Rahman O. PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. Immunotherapy. 2016;8:1081–1089.
   PubMed Web of Science ®Google Scholar
• Vu HL, Rosenbaum S, Purwin TJ, et al. RAC1 P29S regulates PD-L1 expression in melanoma. Pigment Cell Melanoma Res. 2015;28:590–598.
   PubMed Web of Science ®Google Scholar
• Dudley JC, Lin MT, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22:813–820.
   PubMed Web of Science ®Google Scholar
• Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151:1206–1212.
   PubMed Web of Science ®Google Scholar
• Lo JA, Fisher DE, Flaherty KT. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol. 2015;1:1340–1341.
   PubMed Web of Science ®Google Scholar
• Atkinson VG, Ladwa R. Complete responders to anti-PD1 antibodies. What happens when we stop? Ann Oncol. 2016;27:vi383 1116P (abstr).
   Web of Science ®Google Scholar
• Tartari F, Santoni M, Burattini L, et al. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges. Cancer Treat Rev. 2016;48:20–24.
   PubMed Web of Science ®Google Scholar
• Burke T. Clarification on Tartari et al.: economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients. Cancer Treat Rev. 2016;50:82.
   PubMed Web of Science ®Google Scholar
• Ogungbenro K, Patel A, Duncombe R, et al. A rational approach to dose optimisation of pembrolizumab and nivolumab using cost analysis and pharmacokinetic modelling and simulation. Ann Oncol. 2016;27:vi371 1082P (abstr).
   Web of Science ®Google Scholar
• Marriott E, Praet C, Aguiar-Ibanez R, et al. Cost effectiveness of pembrolizumab for unresectable metastatic melanoma after progression with ipilimumab in England. Value Health. 2015;18:A453. PCN 134 Presented at ISPOR 18th Annual Meeting, November 7-11, 2015, Milan, Italy.
   PubMed Web of Science ®Google Scholar
• Silva Miguel L, Vargas Lopes F, Pinheiro B, et al. Cost effectiveness of pembrolizumab for advanced melanoma treatment in Portugal. Value Health. 2016;19:A729. PCN118 Presented at ISPOR 19th Annual Meeting, October 29-November 2, 2016, Vienna, Austria.
   Google Scholar
• Wang J, Chabot I, El-Hadi W, et al. Cost effectiveness of pembrolizumab versus ipilimumab in patients with advanced melanoma in Canada. Value Health. 2016;19:A153–A154. PCN 112 Presented at ISPOR 21th Annual Meeting, May 21-25, 2016, Washington, USA.
   PubMed Web of Science ®Google Scholar
• Wang J, Pellissier J, Xu R, et al. Cost effectiveness of pembrolizumab (Keytruda ®) versus ipilimumab in patients with advanced melanoma in the United States. Value Health. 2016;19:A154. PCN 114 Presented at ISPOR 21th Annual Meeting, May 21-25, 2016, Washington, USA.
   Web of Science ®Google Scholar
• Lu T, Hay JW. Cost effectiveness of pembrolizumab and ipilimumab in advanced melanoma. Value Health. 2016;19:A149. PCN 86 Presented at ISPOR 21th Annual Meeting, May 21-25, 2016, Washington, USA.
   Web of Science ®Google Scholar
• Keytruda: highlights of prescribing information. U.S. Food and drug administration. [cited 2017 Feb 17]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s012lbl.pdf
   Google Scholar
• Keytruda: EPAR summary of product characteristics. European medicines agency. [cited 2017 Feb 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003820/WC500190990.pdf
   Google Scholar
• National Cancer Institute (NCI). Dabrafenib and trametinib followed by ipilimumab and nivolumab or ipilimumab and nivolumab followed by dabrafenib and trametinib in treating patients with stage III-IV BRAFV600 melanoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02224781
   Google Scholar
• Fondazione Melanoma Onlus. Sequential Combo Immuno and Target Therapy (SECOMBIT) study (SECOMBIT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02631447
   Google Scholar
• National Cancer Institute (NCI). Ipilimumab with or without dabrafenib, trametinib, and/or nivolumab in treating patients with melanoma that is metastatic or cannot be removed by surgery. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01940809
   Google Scholar
• Sharp M, Corp D. A study of the safety and efficacy of pembrolizumab (MK-3475) in combination with trametinib and dabrafenib in participants with advanced melanoma (MK-3475-022/KEYNOTE-022). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02130466.
   Google Scholar
• Specenier P. Nivolumab in melanoma. Expert Rev Anticancer Ther. 2016;16:1247–1261..
   PubMed Web of Science ®Google Scholar
• University of Pittsburgh. Neoadjuvant combination biotherapy with pembrolizumab and high dose IFN-alfa2b. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [Cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02339324
   Google Scholar
• Hassane M, Zarour MD. Merck Sharp & Dohme Corp. Melanoma research alliance. Treatment of advanced melanoma with MK-3475 and peginterferon. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02112032
   Google Scholar
• National Cancer Institute (NCI). Immunotherapy using tumor infiltrating lymphocytes for patients with metastatic melanoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01993719
   Google Scholar
• Tesaro, Inc. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients with advanced solid tumors. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://ClinicalTrials.gov/show/NCT02817633
   Google Scholar
• Incyte Corporation. A study of the safety, tolerability, and efficacy of epacadostat administered in combination with nivolumab in select advanced cancers (ECHO-204). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://ClinicalTrials.gov/show/NCT02327078
   Google Scholar
• Incyte Corporation. A phase 3 study of pembrolizumab + epacadostat or placebo in subjects with unresectable or metastatic melanoma (Keynote-252 /ECHO-301). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02752074
   Google Scholar
• NewLink Genetics Corporation. Study of IDO inhibitor in combination with checkpoint inhibitors for adult patients with metastatic melanoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02073123
   Google Scholar
• Celldex Therapeutics. A dose escalation and cohort expansion study of anti-CD27 (Varlilumab) and anti-PD-1 (Nivolumab) in advanced refractory solid tumors. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02335918
   Google Scholar
• M.D. Anderson Cancer Center. APX005M in combination with systemic pembrolizumab in patients with metastatic melanoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02706353
   Google Scholar
• Prima BioMed Australia Pty. Ltd. Phase 1 study of IMP321 adjuvant to anti-PD-1 therapy in unresectable or metastatic melanoma (TACTI-mel). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02676869
   Google Scholar
• Viralytics. Phase I study of intratumoral CAVATAK™ and pembrolizumab in subjects with advanced melanoma (CAPRA). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02565992
   Google Scholar
• M.D. Anderson Cancer Center. dose escalation and cohort expansion of safety and tolerability study of intratumoral rAd.CD40L (ISF35) in combination of systemic pembrolizumab in patients with refractory metastatic melanoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02719015
   Google Scholar
• Dynavax Technologies Corporation. A trial of intratumoral injections of SD-101 in combination with pembrolizumab in patients with metastatic melanoma or recurrent or metastatic head and neck squamous cell carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02521870
   Google Scholar
• Amgen MS, Corp D. Pembrolizumab with or without talimogene laherparepvec or talimogene laherparepvec placebo in unresected melanoma (KEYNOTE-034). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02263508
   Google Scholar
• National Cancer Institute (NCI). Talimogene laherparepvec and pembrolizumab in treating patients with stage III-IV melanoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02965716
   Google Scholar
• M.D. Anderson Cancer Center. Neoadjuvant and adjuvant checkpoint blockade in patients with clinical stage III or oligometastatic stage IV melanoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02519322
   Google Scholar
• Safran H. Brown University, Rhode Island Hospital, The Miriam Hospital. BrUOG 324: adjuvant nivolumab and low dose ipilimumab for stage III and resected stage IV melanoma: a phase ii brown university oncology research group trial. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02656706
   Google Scholar
• The Netherlands Cancer Institute. Study to identify the optimal adjuvant combination scheme of ipilimumab and nivolumab in melanoma patients (OpACIN). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 Feb 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02437279
   Google Scholar